This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Abeona Therapeutics, Inc.
Drug Names(s): OSI-7836, SR9025, 4'-thio-araC, GS7836
Description: OSI-7836 is a member of the nucleoside analog class of cytotoxic chemotherapeutics of which gemcitabine (Eli Lilly's Gemzar) is the market leader. OSI is developing OSI-7836 with the hopes of its becoming a next-generation gemcitabine. Gemzar has been approved for the treatment of pancreatic cancer since May 1996 and non-small cell lung cancer since August 1998, and is in clinical trials for the treatment of various solid tumors.
Deal Structure: OSI-7836 was originally developed by OSI Pharmaceuticals.
As of August 2009, Access Pharmaceuticals has been licensed the rights to OSI-7836 from Southern Research Institute.
Additional information available to subscribers only: